PTC THERAPEUTICS, INC. 8-K

What Happened
PTC Therapeutics, Inc. (PTCT) filed an 8-K reporting results from its Annual Meeting held June 2, 2026 (record date April 10, 2026). Stockholders elected four Class I directors to terms through the 2029 annual meeting: Jessica Chutter, Matthew B. Klein, M.D., M.S., F.A.C.S., Stephanie S. Okey, M.S., and Jerome B. Zeldis, M.D., Ph.D. The firm also ratified Ernst & Young LLP as its independent registered public accounting firm for fiscal 2026 and approved the non‑binding advisory vote on executive compensation (say-on-pay).

Key Details

• Shares outstanding as of record date: 82,911,783. Meeting date: June 2, 2026.
• Director vote totals (For / Withheld; broker non-votes = 3,858,311):
  • Jessica Chutter: 71,945,515 For; 737,780 Withheld.
  • Matthew B. Klein: 71,550,878 For; 1,132,417 Withheld.
  • Stephanie S. Okey: 68,902,707 For; 3,780,588 Withheld.
  • Jerome B. Zeldis: 69,821,943 For; 2,861,352 Withheld.
• Auditor ratification: Ernst & Young LLP ratified — 76,170,292 For; 355,794 Against; 15,520 Abstained.
• Say-on-pay (non-binding): Approved — 71,166,204 For; 1,492,801 Against; 24,290 Abstained; 3,858,311 broker non-votes.

Why It Matters
These results confirm board continuity through 2029 and shareholder support for PTC’s governance and executive pay policies. Ratifying Ernst & Young keeps the company’s auditor in place for fiscal 2026, which affects audit continuity and financial reporting. The presence of several million broker non‑votes on non‑routine items indicates some institutional or broker-held shares did not vote on those proposals; however, the key proposals received majority support.